Core Viewpoint - 康圣环球 (09960.HK) is expected to report a net loss of approximately RMB 30 million to RMB 35 million for the first half of 2025, compared to a net profit of about RMB 10.5 million for the same period in 2024 [1] Financial Performance - The anticipated net loss is primarily due to a revenue decline of RMB 16.4 million, representing a 3.5% decrease compared to the first half of 2024 [1] - The company expects a loss of approximately RMB 10.15 million from fair value changes in its invested funds [1] - An estimated credit loss of RMB 8.42 million is anticipated related to accounts receivable from COVID-19 business [1] - The acquisition of Guangzhou Benchmark Medical Co., Ltd. and Guangzhou Kangcheng Weiye Biotechnology Co., Ltd. is expected to incur additional expenses and result in a combined loss of approximately RMB 16 million for the first half of 2025 [1] Business Stability - Despite the anticipated losses, the core business of the group remains stable when excluding the aforementioned factors [1]
康圣环球(09960.HK)预计上半年净亏损约3000万至3500万元